In a profile on Nanosphere, Seeking Alpha’s Cory Renauer concludes:
“As a long term investor, I see gold in its Verigene® System, both literally and figuratively. Its current number of diagnostics already cleared by major regulators, make it a cost effective addition to almost any hospital based laboratory. Furthermore, its 24/7 availability, and rapid turnaround will save lives, lots of them.
I don’t know of any device on the market, or in development, that effectively performs a fraction of the diagnostics that the Verigene System is capable of, and that number is growing. Early adoption and the company’s patent portfolio should provide Nanosphere with a long term competitive advantage. The company should be able to enjoy very healthy profit margins on its test cartridges for years. Stir in the company’s top-notch management team and you’ve got a recipe for a very attractive investment.”
The complete article is available at Seeking Alpha.
